[211At]AITM-based therapy not only reduces mGluR1 expression but also induces cancer senescence through reprogrammed senescence-associated secretory phenotype (SASP) variants, which together modulate cell fate through phenotypic changes in synergy with genetic alterations.11 This evidence concerns the gene GRM1 and cancer.